Shots:
- Genentech has reported P-III (lidERA Breast Cancer) trial assessing giredestrant (QD) vs SoC endocrine therapy in pts (n=~4,100) with medium or high-risk stage I-III ER+, HER2- breast cancer
- Trial met its 1EP of improved invasive disease-free survival & showed a favorable OS trend; OS data remains immature. Results to be presented in future meetings & shared with global health authorities
- Giredestrant is a selective estrogen receptor degrader & full antagonist, which is being evaluated in P-III (evERA Breast Cancer) trial with everolimus, P-III (persevERA Breast Cancer) with palbociclib, P-III (pionERA Breast Cancer) trial with a CDK 4/6 inhibitor, & P-III (heredERA Breast Cancer) trial with dual HER2 blockade
Ref: Genentech| Image: Genentech| Press Release
Related News:- Genentech (Roche) Reveals P-III Trials Findings on Fenebrutinib in Relapsing and Primary Progressive Multiple Sclerosis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
